Biotech Investors & VC Firms in North America
1593 firms in this list, with a median first check of $500K. 347 of them lead rounds. Generated from verified public data and updated continuously.
Altaris Capital Partners
New York
22 people
Rhapsody Venture Partners
CambridgePre-Seed–Seed$500K – $2M
10 people
Starlight Ventures
MiamiPre-Seed–Series B$100K – $3M
7 people
Unorthodox Ventures
AustinSeed–Growth$1M – $5M
15 people
Delaware Crossing Investor Group
PhiladelphiaSeed–Series A
5 people
Taiwan Global Angels
BerkeleyPre-Seed–Series B$300K – $3M
19 people
DeepWork Capital
OrlandoSeed–Series B
12 people
Venture Ontario
TorontoSeed–Growth
3 people
Catalytic Impact Foundation
HinghamPre-Seed–Series A
8 people
Spring Angels Capital
VancouverPre-Seed–Seed
26 people
Olima Ventures
WashingtonPre-Seed–Series A
2 people
Wormhole Capital
Pre-Seed–Growth
2 people
University of Cambridge Enterprise
CambridgePre-Seed–Series A
13 people
H.I.G. HealthBridge Partners
MiamiGrowth$5M – $40M
15 people
Dimension Capital
San FranciscoSeed–Growth$1M – $10M
14 people
Ocean Azul Partners
Coral GablesSeed–Series A$500K – $2M
8 people
Accelmed Partners
MiamiSeries A–Growth
10 people
Necessary Ventures
San FranciscoPre-Seed–Seed$1M – $2M
10 people
Avalon BioVentures
La JollaPre-Seed–Seed
18 people
Oncology Ventures
New YorkSeed–Series A
17 people
BIOSPRING PARTNERS
New YorkGrowth
22 people
Deviation Capital
New YorkSeed–Series A
16 people
Medical Excellence Capital
New YorkSeed–Series B
19 people
MSD Global Health Innovation Fund
RahwaySeries A–Late Stage$2M – $10M
10 people
Related lists
Investors & VC Firms in North America (13518)Investors & VC Firms in United States (12555)Investors & VC Firms in Europe (5846)Investors & VC Firms in Global (4720)AI & Machine Learning Investors & VC Firms (4549)Fintech Investors & VC Firms (4537)SaaS Investors & VC Firms (4215)Healthtech Investors & VC Firms (4185)Enterprise Software Investors & VC Firms (4097)Crypto & Web3 Investors & VC Firms (3965)
Data sourced from public filings and firms' own websites — see our methodology.







































































































